Skip to main content
Science Catalogs
Health Sciences

Dual-action compound raises energy expenditure and spares muscle in obese mice

A compound first described in the 1970s may offer a different route to treating obesity, according to researchers at the University of California, Berkeley. In obese mice, the molecule 5-tetradecyloxy-2-furoic acid (TOFA) increased energy expenditure by up to 18%, reduced body fat without a significant loss of lean mass, and improved blood sugar control. The work appears in Science Advances, and its effects in humans remain untested.

Targeting energy output rather than appetite

GLP-1-based drugs such as semaglutide and tirzepatide act mainly by lowering appetite and food intake. They have changed obesity and diabetes care, but they can cause digestive side effects, and the reduced eating that drives weight loss may also contribute to loss of muscle mass. Over time, excessive muscle loss can add to weakness and frailty.

The Berkeley group, led by senior author Anders Näär, professor of metabolic biology and nutrition, asked whether the other side of the energy balance equation could be adjusted instead: how much energy the body spends. Näär has described body weight as responding to two levers, intake and expenditure, with GLP-1 drugs acting almost entirely on the first.

One molecule, two actions

TOFA belongs to the class of acetyl-CoA carboxylase (ACC) inhibitors, which block enzymes involved in making fatty acids. Other ACC inhibitors have reached mid-stage clinical trials, but none has been approved for metabolic disease. A recurring problem is that many raise blood triglycerides, which could increase cardiovascular risk.

The team found that TOFA also activates two nuclear receptors, PPARα and PPARδ, which regulate genes for fatty acid uptake and oxidation. The compound therefore both curbs lipid synthesis and promotes the burning of fat already available. Unlike other ACC inhibitors, it did not raise triglycerides in the mice, which the authors suggest may be linked to this additional activity.

First author Justin Y. Lee, now at UCSF, said the compound appears to engage a coordinated metabolic response rather than simply blocking lipid synthesis.

Findings in mice

In obese mice, TOFA treatment:

  • increased insulin sensitivity;
  • lowered triglyceride levels;
  • improved features of fatty liver disease;
  • reduced fat mass without a significant fall in lean muscle mass;
  • raised energy expenditure by up to 18%, without greater physical activity or a rise in body temperature.

The researchers also tested whether the effect could be reproduced by giving two separate compounds, one blocking lipid production and the other stimulating energy expenditure. This combination improved metabolic health less than TOFA alone, which suggests that delivering both actions in a single molecule matters.

Combination with GLP-1 drugs

When TOFA was given alongside semaglutide or tirzepatide in mice, the combinations produced larger improvements in body weight, glucose regulation, insulin levels and triglycerides than either approach used alone. Näär said the effects were additive or synergistic, and that the team sees TOFA as complementary to appetite-suppressing drugs rather than a replacement.

Limitations and next steps

All results so far come from animal experiments. The safety and efficacy of TOFA in people have not been established, and it is unclear whether the energy expenditure effect, or the muscle-sparing profile, will carry over to humans. Mouse metabolism differs considerably from human metabolism, so clinical trials will be needed to test these points and to judge whether the compound offers a real advantage over existing treatments.

The researchers have founded a company, ReRx Therapeutics, to pursue clinical development, supported by Nucleate and Berkeley SkyDeck. For metabolic researchers, the study offers a case for compounds that combine enzyme inhibition with receptor activation, and for examining body composition, not only weight, when assessing new obesity therapies. Co-authors came from Berkeley, Massachusetts General Hospital, the University of California, San Diego, the Helmholtz Center Munich and ReRx Therapeutics.

Source: Experimental compound burns fat without sacrificing muscle (ScienceDaily: top science, 20 November 2026).

Image: AI-generated illustration.

Working on this topic? Find a journal for your research or join the discussion on Scholars Post.